Verdence Capital Advisors LLC Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Verdence Capital Advisors LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,481 shares of the medical research company’s stock after buying an additional 248 shares during the period. Verdence Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,817,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Revolve Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. Root Financial Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 5.0% in the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock worth $252,000 after purchasing an additional 24 shares during the period. Rossmore Private Capital increased its holdings in shares of Thermo Fisher Scientific by 0.5% in the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock worth $2,315,000 after purchasing an additional 24 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its holdings in shares of Thermo Fisher Scientific by 3.1% in the second quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock worth $326,000 after purchasing an additional 24 shares during the period. Finally, Somerville Kurt F increased its holdings in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Somerville Kurt F now owns 1,605 shares of the medical research company’s stock worth $651,000 after purchasing an additional 25 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 over the last three months. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TMO shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Finally, HSBC reiterated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $589.10.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $524.80 on Tuesday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $198.17 billion, a PE ratio of 30.35, a P/E/G ratio of 2.85 and a beta of 0.77. The firm has a fifty day simple moving average of $489.83 and a two-hundred day simple moving average of $447.66. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.